Sofosbuvir and ledipasvir for HIV/HCV co-infected patients.

ABSTRACT:

Introduction

Hepatitis C virus (HCV) is a chronic infection that disproportionately impacts people living with HIV. In the past, HCV therapy was less effective in individuals with HIV co-infection. However, the advent of direct-acting antivirals has revolutionized HCV treatment with high rates of success in patients both with and without HIV.

Areas covered

In this paper, we review the evidence supporting the use of ledipasvir and sofosbuvir (LDV/SOF) for the treatment of HCV in patients with HIV co-infection. Articles searchable on MEDLINE/PubMed were reviewed to provide context for use of LDV/SOF in individuals with HCV and HIV co-infection.

Expert opinion

This treatment is highly effective in achieving HCV cure or sustained virologic response, however further studie

SUBMITTER: Rosenthal ES 

PROVIDER: S-EPMC4930150 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature